deltatrials
Recruiting PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04749108

Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma (GRECCAR14)

Multicentric Phase II-III Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma After a Favorable Response to Induction Chemotherapy

Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle

Conditions Locally Advanced Malignant Neoplasm Rectal Carcinoma
Interventions Early tumor response evaluation by MRI volumetry Induction chemotherapy - modified FOLFIRINOX regimen Radical proctectomy with total mesorectal excision Radiochemotherapy Cap 50
Updated 17 times since 2021 Last updated: Feb 3, 2026 Started: Nov 26, 2021 Primary completion: Aug 31, 2026 Completion: Aug 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Locally Advanced Malignant Neoplasm and Rectal Carcinoma and is currently actively recruiting participants. Institut du Cancer de Montpellier - Val d'Aurelle leads this study, which shows 17 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jun 2023 · 6 months · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Dec 2025 · 12 months · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

17 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE2/PHASE3

  2. Dec 2025 — Feb 2026 [monthly]

    Recruiting PHASE2/PHASE3

  3. Dec 2024 — Dec 2025 [monthly]

    Recruiting PHASE2/PHASE3

  4. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE2/PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

▶ Show 12 earlier versions

  1. Oct 2023 — Jul 2024 [monthly]

    Recruiting PHASE2_PHASE3

  2. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2_PHASE3

  3. Jun 2023 — Sep 2023 [monthly]

    Recruiting PHASE2_PHASE3

  4. Dec 2022 — Jun 2023 [monthly]

    Recruiting PHASE2_PHASE3

  5. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2_PHASE3

  6. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2_PHASE3

  7. Jan 2022 — Sep 2022 [monthly]

    Recruiting PHASE2_PHASE3

    Status: Not Yet Recruiting → Recruiting

  8. Dec 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

  9. Sep 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

  10. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

  11. May 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

  12. Mar 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institut du Cancer de Montpellier - Val d'Aurelle
Data source: Institut du Cancer de Montpellier - Val d'Aurelle

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Annecy, France , Besançon, France , Bordeaux, France , Clermont-Ferrand, France , Dijon, France , Grenoble, France , Le Kremlin-Bicêtre, France , Lille, France , Lyon, France and 11 more locations